Abstract
To investigate the maternal-fetal transfer of Cephamandole (CMD) and its distribution in the fetus, we administered a single 1000 mg 1.M. dose to 35 pregnant women (14-I trimester, 21-II trimester) 25 minutes to 17 hours prior to therapeutic abortion and sterilization by hysterectomy. CMD concentration was assayed microbiologically in maternal serum, myometrium, fetal tissues (placenta, brain, lung, liver, kidney) and fetal fluids (amniotic, CSF, urine and serum). Maternal serum half-life was 2.4 hours while peak serum concentration was 19 ug/ml at 1 hour and 1.5 ug/ml at 8 hours. Mean Fetal serum CMD concentrations were 25% of maternal serum at 1 hour, 30% at 2 hours, 44% at 4 hours and equal at 9.5 hours. There was no detectable CMD (<0.8 ug/ml or gm) level in fetal: brain (19 samples) and CSF (21 samples), liver (28 samples), lung (16 samples), urine (6 samples), amniotic fluid (29 samples). Of 10 fetal kidneys, only 2-II trimester (13 and 19 weeks' G.A.) had detectable levels of 1.4 and 1.35 ug at 1 3/4 and 3½ hours respectively. Placental concentrations of CMD ranged from 0.9 ug/gm to 3.6 ug/gm only between 1 and 4 hours of the study and otherwise was not detectable. CMD does not have a wide distribution in the fetus of the first-half of gestation following maternal dosing and would be useful for treatment of susceptible maternal infections.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernard, B., Caudillo, G., Thielen, P. et al. 314 CEPHAMANDOLE: MATERNAL-FETAL PHARMACOLOGY. Pediatr Res 15 (Suppl 4), 492 (1981). https://doi.org/10.1203/00006450-198104001-00325
Issue Date:
DOI: https://doi.org/10.1203/00006450-198104001-00325